JP2016523256A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523256A5
JP2016523256A5 JP2016521574A JP2016521574A JP2016523256A5 JP 2016523256 A5 JP2016523256 A5 JP 2016523256A5 JP 2016521574 A JP2016521574 A JP 2016521574A JP 2016521574 A JP2016521574 A JP 2016521574A JP 2016523256 A5 JP2016523256 A5 JP 2016523256A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
mammal
pharmaceutically acceptable
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016521574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523256A (ja
JP6525162B2 (ja
Filing date
Publication date
Priority claimed from US13/921,895 external-priority patent/US9266838B2/en
Application filed filed Critical
Priority claimed from PCT/US2014/043179 external-priority patent/WO2014205213A1/en
Publication of JP2016523256A publication Critical patent/JP2016523256A/ja
Publication of JP2016523256A5 publication Critical patent/JP2016523256A5/ja
Application granted granted Critical
Publication of JP6525162B2 publication Critical patent/JP6525162B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016521574A 2013-06-19 2014-06-19 ヒストン脱メチル化酵素阻害剤としての置換(e)−n’−(1−フェニルエチリデン)ベンゾヒドラジド類似体 Expired - Fee Related JP6525162B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/921,895 2013-06-19
US13/921,895 US9266838B2 (en) 2011-08-15 2013-06-19 Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
PCT/US2014/043179 WO2014205213A1 (en) 2013-06-19 2014-06-19 Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors

Publications (3)

Publication Number Publication Date
JP2016523256A JP2016523256A (ja) 2016-08-08
JP2016523256A5 true JP2016523256A5 (https=) 2017-07-27
JP6525162B2 JP6525162B2 (ja) 2019-06-05

Family

ID=52105283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521574A Expired - Fee Related JP6525162B2 (ja) 2013-06-19 2014-06-19 ヒストン脱メチル化酵素阻害剤としての置換(e)−n’−(1−フェニルエチリデン)ベンゾヒドラジド類似体

Country Status (13)

Country Link
EP (1) EP3010915B1 (https=)
JP (1) JP6525162B2 (https=)
KR (1) KR102288648B1 (https=)
CN (2) CN110015984A (https=)
AU (1) AU2014281398B2 (https=)
BR (1) BR112015032113B1 (https=)
CA (1) CA2915817C (https=)
ES (1) ES2739814T3 (https=)
IL (1) IL243200B (https=)
MX (1) MX366949B (https=)
NZ (1) NZ715331A (https=)
SG (2) SG11201510376QA (https=)
WO (1) WO2014205213A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015032113B1 (pt) * 2013-06-19 2019-01-29 University Of Utah Research Foundation análogos de (e)-n’-(1-feniletilideno)benzohidrazida substituídos como inibidores de histona demetilase
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Lsd1阻害剤としてのシクロプロピルアミン類
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016119031A1 (pt) * 2015-01-29 2016-08-04 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
AU2016275702A1 (en) 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
CN108727377A (zh) * 2017-04-14 2018-11-02 四川大学 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
FI3661510T3 (fi) 2017-08-03 2024-12-18 Oryzon Genomics Sa Menetelmiä käyttäytymismuutosten hoitamiseksi
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
CN108689960B (zh) * 2018-06-07 2022-03-04 济南大学 5-苯亚甲基-2-苯基噻唑酮类化合物及其制备和应用
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US20220151999A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
LT3941466T (lt) 2019-03-20 2026-02-25 Oryzon Genomics, S.A. Vafidemstatas ribinio asmenybės sutrikimo simptomų, nesusijusių su agresija, gydymui
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
CN110850104B (zh) * 2020-01-15 2020-06-05 上海众启生物科技有限公司 用于阿尔兹海默症自身抗体检测的蛋白抗原组合及其应用
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
US20250073232A1 (en) 2021-04-08 2025-03-06 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN116444437B (zh) * 2023-03-08 2025-09-16 曲靖师范学院 抗癌医药达洛鲁胺的合成方法
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法
WO2025188857A1 (en) * 2024-03-05 2025-09-12 University Of Florida Research Foundation, Incorporated Hdac8 degraders and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519794A2 (pt) * 2005-01-07 2009-03-17 Hoffmann La Roche derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos
WO2006136008A1 (en) * 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
WO2007008143A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2010083314A2 (en) * 2009-01-14 2010-07-22 Dow Agrosciences Llc Fungicidal compositions including hydrazone derivatives and copper
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
US20110189306A1 (en) * 2010-01-13 2011-08-04 Norbert Kartner COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES
JP2014500254A (ja) * 2010-11-09 2014-01-09 セルゾーム リミティッド Tyk2阻害剤としてのピリジン化合物およびそのアザ類似体
SI2744330T1 (sl) * 2011-08-15 2020-11-30 University Of Utah Research Foundation Substituirani (E)-N'-(1-feniletiliden) benzohidrazidni analogi kot inhibitorji histon-demetilaze
BR112015032113B1 (pt) * 2013-06-19 2019-01-29 University Of Utah Research Foundation análogos de (e)-n’-(1-feniletilideno)benzohidrazida substituídos como inibidores de histona demetilase

Similar Documents

Publication Publication Date Title
JP2016523256A5 (https=)
JP2015537020A5 (https=)
EA201490357A1 (ru) Индазолы
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
TN2015000121A1 (en) Gdf-8 inhibitors
NZ588994A (en) Phenyl and benzodioxinyl substituted indazoles derivatives
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
PH12018501849A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
MX2010006421A (es) Compuestos organicos.
NZ769042A (en) Compositions and methods for treating cns disorders
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
DOP2014000058A (es) 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
MX2015008187A (es) Inhibidores de alk deuterados.
MX2013008212A (es) Derivados de 7-azaindol.
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
MX2014000783A (es) Compuestos de piridazinona y su uso como inhibidores de la enzima d-aminoacido oxidasa (daao).
PH12019502605A1 (en) Glucuronide prodrugs of janus kinase inhibitors
TN2012000595A1 (en) Substituted triazolopyridines
NZ605827A (en) Co-crystals and salts of ccr3-inhibitors
PH12019502853A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.